JPS55164685A - Novel maytansinoid compound and its preparation - Google Patents

Novel maytansinoid compound and its preparation

Info

Publication number: JPS55164685A
Authority: JP; Japan
Prior art keywords: formula; agent; maytansinol; useful; preparation
Prior art date: 1979-06-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP7281179A

Other languages

English (en)

Inventor

Osamu Miyashita

Hiroshi Akimoto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Ltd

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-06-08

Filing date

1979-06-08

Publication date

1980-12-22

1979-06-08 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

1979-06-08 Priority to JP7281179A priority Critical patent/JPS55164685A/ja

1980-05-22 Priority to US06/152,392 priority patent/US4317821A/en

1980-06-06 Priority to EP80103138A priority patent/EP0021178B1/en

1980-06-06 Priority to CA000353518A priority patent/CA1135260A/en

1980-06-06 Priority to DE8080103138T priority patent/DE3066149D1/de

1980-06-06 Priority to AT80103138T priority patent/ATE5885T1/de

1980-12-22 Publication of JPS55164685A publication Critical patent/JPS55164685A/ja

Status Pending legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title abstract 3
QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 abstract 2
QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 abstract 2
AWOGJGCWCWKEES-NKPLSRDGSA-N (2s,4r)-1-[(2s)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]-4-(7-methoxy-2-phenylquinolin-4-yl)oxypyrrolidine-2-carboxylic acid Chemical compound C=1C(C=2C=CC=CC=2)=NC2=CC(OC)=CC=C2C=1O[C@@H]1C[C@@H](C(O)=O)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C1 AWOGJGCWCWKEES-NKPLSRDGSA-N 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
229940121375 antifungal agent Drugs 0.000 abstract 1
239000003429 antifungal agent Substances 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
125000001589 carboacyl group Chemical group 0.000 abstract 1
150000001718 carbodiimides Chemical class 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
231100000053 low toxicity Toxicity 0.000 abstract 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical group [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
230000000394 mitotic effect Effects 0.000 abstract 1
230000004083 survival effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

JP7281179A 1979-06-08 1979-06-08 Novel maytansinoid compound and its preparation Pending JPS55164685A (en)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
JP7281179A JPS55164685A (en)	1979-06-08	1979-06-08	Novel maytansinoid compound and its preparation
US06/152,392 US4317821A (en)	1979-06-08	1980-05-22	Maytansinoids, their use and pharmaceutical compositions thereof
EP80103138A EP0021178B1 (en)	1979-06-08	1980-06-06	Maytansinoids, their production and use
CA000353518A CA1135260A (en)	1979-06-08	1980-06-06	Maytansinoids, their production and use
DE8080103138T DE3066149D1 (en)	1979-06-08	1980-06-06	Maytansinoids, their production and use
AT80103138T ATE5885T1 (de)	1979-06-08	1980-06-06	Maytansinoide, ihre herstellung und verwendung.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP7281179A JPS55164685A (en)	1979-06-08	1979-06-08	Novel maytansinoid compound and its preparation

Publications (1)

Publication Number	Publication Date
JPS55164685A true JPS55164685A (en)	1980-12-22

Family

ID=13500153

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP7281179A Pending JPS55164685A (en)	1979-06-08	1979-06-08	Novel maytansinoid compound and its preparation

Country Status (6)

Country	Link
US (1)	US4317821A (ja)
EP (1)	EP0021178B1 (ja)
JP (1)	JPS55164685A (ja)
AT (1)	ATE5885T1 (ja)
CA (1)	CA1135260A (ja)
DE (1)	DE3066149D1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008528493A (ja) *	2005-01-21	2008-07-31	イミュノジェン・インコーポレーテッド	メイタンシノイドエステル類を調製するための方法

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57192389A (en)	1981-05-20	1982-11-26	Takeda Chem Ind Ltd	Novel maytansinoid
BR0012196A (pt)	1999-06-25	2002-03-19	Genentech Inc	Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7097840B2 (en)	2000-03-16	2006-08-29	Genentech, Inc.	Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
AU2002311919B8 (en)	2001-05-11	2007-03-22	Ludwig Institute For Cancer Research Ltd	Specific binding proteins and uses thereof
US20110313230A1 (en)	2001-05-11	2011-12-22	Terrance Grant Johns	Specific binding proteins and uses thereof
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7803915B2 (en) *	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
PT2000545E (pt)	2001-06-20	2011-12-21	Genentech Inc	Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
US20040235068A1 (en) *	2001-09-05	2004-11-25	Levinson Arthur D.	Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
DE60238143D1 (de)	2001-09-18	2010-12-09	Genentech Inc	Zusammensetzungen und verfahren für die diagnose von tumoren
US8603514B2 (en)	2002-04-11	2013-12-10	Monosol Rx, Llc	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900498B2 (en)	2001-10-12	2014-12-02	Monosol Rx, Llc	Process for manufacturing a resulting multi-layer pharmaceutical film
US20190328679A1 (en)	2001-10-12	2019-10-31	Aquestive Therapeutics, Inc.	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en)	2001-10-12	2008-04-15	Monosol Rx, Llc	Process for making an ingestible film
US20110033542A1 (en)	2009-08-07	2011-02-10	Monosol Rx, Llc	Sublingual and buccal film compositions
US11207805B2 (en)	2001-10-12	2021-12-28	Aquestive Therapeutics, Inc.	Process for manufacturing a resulting pharmaceutical film
US10285910B2 (en)	2001-10-12	2019-05-14	Aquestive Therapeutics, Inc.	Sublingual and buccal film compositions
US8900497B2 (en)	2001-10-12	2014-12-02	Monosol Rx, Llc	Process for making a film having a substantially uniform distribution of components
US20070281003A1 (en)	2001-10-12	2007-12-06	Fuisz Richard C	Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8765167B2 (en)	2001-10-12	2014-07-01	Monosol Rx, Llc	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110045005A1 (en)	2001-10-19	2011-02-24	Craig Crowley	Compositions and methods for the treatment of tumor of hematopoietic origin
AU2002367318B2 (en)	2002-01-02	2007-07-12	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
JP2005536190A (ja)	2002-04-16	2005-12-02	ジェネンテック・インコーポレーテッド	腫瘍の診断と治療のための組成物と方法
US20090068178A1 (en) *	2002-05-08	2009-03-12	Genentech, Inc.	Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
WO2004101756A2 (en)	2003-05-09	2004-11-25	Diadexus, Inc.	Ovr110 antibody compositions and methods of use
US8088387B2 (en) *	2003-10-10	2012-01-03	Immunogen Inc.	Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MXPA05011811A (es)	2003-05-20	2006-02-17	Immunogen Inc	Agentes citotoxicos mejorados que comprenden nuevos maitansinoides.
KR20130065723A (ko)	2003-06-27	2013-06-19	암젠 프레몬트 인코포레이티드	상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
EP2784084B2 (en)	2003-07-08	2023-10-04	Novartis Pharma AG	Antagonist antibodies to IL-17A/F heterologous polypeptides
AU2004261980A1 (en) *	2003-08-01	2005-02-10	Genentech, Inc.	Antibody CDR polypeptide sequences with restricted diversity
DK2295073T3 (da)	2003-11-17	2014-07-28	Genentech Inc	Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse
PT1718677E (pt)	2003-12-19	2012-07-18	Genentech Inc	Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
NZ579482A (en)	2004-06-01	2011-02-25	Genentech Inc	Antibody drug conjugates and methods
SI1771474T1 (sl)	2004-07-20	2010-06-30	Genentech Inc	Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
MX2007001064A (es)	2004-07-26	2007-04-12	Genentech Inc	Metodos y composiciones para modular la activacion del factor de crecimiento de hepatocitos.
CA2486285C (en) *	2004-08-30	2017-03-07	Viktor S. Goldmakher	Immunoconjugates targeting syndecan-1 expressing cells and use thereof
WO2006026759A2 (en) *	2004-09-03	2006-03-09	Genentech, Inc.	Humanized anti-beta7 antagonists and uses therefor
EP2230517A1 (en)	2005-01-07	2010-09-22	Diadexus, Inc.	OVR110 antibody compositions and methods of use
WO2006132788A2 (en)	2005-06-06	2006-12-14	Genentech, Inc.	Transgenic models for different genes and their use for gene characterization
EP1922410A2 (en)	2005-08-15	2008-05-21	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
ES2577292T3 (es)	2005-11-07	2016-07-14	Genentech, Inc.	Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1962584A2 (en)	2005-11-21	2008-09-03	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
BRPI0619118A2 (pt)	2005-12-02	2011-09-13	Genentech Inc	composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
EP1973951A2 (en) *	2005-12-02	2008-10-01	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
CA2631327C (en) *	2005-12-02	2015-10-13	Genentech, Inc.	Her2 binding polypeptides and uses thereof
CA2633887C (en)	2005-12-15	2015-12-22	Genentech, Inc.	Methods and compositions for targeting polyubiquitin
BRPI0706840A2 (pt)	2006-01-05	2011-04-05	Genentech Inc	anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
SI1976884T1 (sl)	2006-01-20	2013-04-30	Genetech, Inc.	Anti-efrinB2 protitelesa in postopki uporabe le teh
EP2050335A1 (en)	2006-02-17	2009-04-22	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
AU2007243946B2 (en)	2006-04-05	2012-11-29	Curis, Inc.	Method for using BOC/CDO to modulate hedgehog signaling
CA2649387A1 (en)	2006-04-19	2008-03-27	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
EP2032606B1 (en)	2006-05-30	2013-11-27	Genentech, Inc.	Antibodies and immunoconjugates and uses therefor
ES2372217T3 (es)	2006-09-12	2012-01-17	Genentech, Inc.	Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
BRPI0717638A2 (pt)	2006-10-27	2013-11-12	Genentech Inc	Anticorpors e imunoconjugados e usos para os mesmos
JP5391073B2 (ja)	2006-11-27	2014-01-15	ディアデクサスインコーポレーテッド	Ｏｖｒ１１０抗体組成物および使用方法
US9090693B2 (en) *	2007-01-25	2015-07-28	Dana-Farber Cancer Institute	Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
MX2009008430A (es)	2007-02-09	2009-10-28	Genentech Inc	Anticuerpos anti-robo4 y sus usos.
CA2680854C (en) *	2007-03-15	2017-02-14	Ludwig Institute For Cancer Research	Treatment method using egfr antibodies and src inhibitors and related formulations
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PE20090943A1 (es)	2007-07-16	2009-08-05	Genentech Inc	Anticuerpos anti-cd79b e inmunoconjugados
EP2176295B1 (en)	2007-07-16	2014-11-19	Genentech, Inc.	Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CN108424454B (zh)	2007-08-14	2022-05-31	路德维格癌症研究所有限公司	靶向egf受体的单克隆抗体175及其衍生物和用途
US20110033476A1 (en) *	2007-11-12	2011-02-10	Theraclone Sciences Inc.	Compositions and methods for the therapy and diagnosis of influenza
JP4932940B2 (ja)	2007-11-12	2012-05-16	セラクローンサイエンシーズ，インコーポレイテッド	インフルエンザの治療および診断のための組成物および方法
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
WO2009080832A1 (en) *	2007-12-26	2009-07-02	Biotest Ag	Methods and agents for improving targeting of cd138 expressing tumor cells
WO2009080831A1 (en) *	2007-12-26	2009-07-02	Biotest Ag	Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
CN101965366B (zh) *	2007-12-26	2016-04-27	生物测试股份公司	靶向cd138的免疫缀合物及其应用
US9221914B2 (en)	2007-12-26	2015-12-29	Biotest Ag	Agents targeting CD138 and uses thereof
CN101977934B (zh)	2008-01-18	2014-09-17	健泰科生物技术公司	用于靶向k63连接的多聚遍在蛋白的方法和组合物
KR101607346B1 (ko)	2008-01-31	2016-03-29	제넨테크, 인크.	항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
AU2009223688B2 (en) *	2008-03-10	2014-12-11	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
DK2644194T3 (en)	2008-03-18	2017-07-03	Genentech Inc	Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
SG10202112838YA (en)	2008-04-09	2021-12-30	Genentech Inc	Novel compositions and methods for the treatment of immune related diseases
KR101361905B1 (ko) *	2008-05-16	2014-02-21	제넨테크, 인크.	베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
ES2442024T3 (es)	2008-07-15	2014-02-07	Academia Sinica	Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
AR073717A1 (es)	2008-10-01	2010-11-24	Genentech Inc	Anticuerpos anti-notch2 de murino y humano, y metodos de uso
KR20110101212A (ko)	2008-12-17	2011-09-15	제넨테크, 인크.	Ｃ형 간염 바이러스 조합 요법
SI3260136T1 (sl)	2009-03-17	2021-05-31	Theraclone Sciences, Inc.	Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
MY152068A (en)	2009-03-20	2014-08-15	Genentech Inc	Bispecific anti-her antibodies
MA33208B1 (fr)	2009-03-25	2012-04-02	Genentech Inc	Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
RU2587621C2 (ru)	2009-04-01	2016-06-20	Дженентек, Инк.	АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CA2756244A1 (en)	2009-04-02	2010-10-07	Roche Glycart Ag	Multispecific antibodies comprising full length antibodies and single chain fab fragments
US8609101B2 (en) *	2009-04-23	2013-12-17	Theraclone Sciences, Inc.	Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
EP2432803A2 (en)	2009-05-20	2012-03-28	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
EP2711018A1 (en)	2009-06-22	2014-03-26	MedImmune, LLC	Engineered Fc regions for site-specific conjugation
NZ597531A (en)	2009-07-31	2014-05-30	Genentech Inc	Inhibition of tumor metastasis using bv8- or g-csf-antagonists
CA2772715C (en)	2009-09-02	2019-03-26	Genentech, Inc.	Mutant smoothened and methods of using the same
EP2478013B1 (en)	2009-09-16	2018-10-24	F.Hoffmann-La Roche Ag	Coiled coil and/or tether containing protein complexes and uses thereof
US20110076232A1 (en) *	2009-09-29	2011-03-31	Ludwig Institute For Cancer Research	Specific binding proteins and uses thereof
MX2012002013A (es)	2009-10-19	2012-03-16	Genentech Inc	Moduladores de activador del factor de crecimiento de hepatocitos.
JP5819308B2 (ja)	2009-10-22	2015-11-24	ジェネンテック，インコーポレイテッド	マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
RU2559533C2 (ru)	2009-10-22	2015-08-10	Дженентек, Инк.	Антитела против гепсина и способы их применения
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
EP2496601B1 (en)	2009-11-05	2017-06-07	F. Hoffmann-La Roche AG	Methods and composition for secretion of heterologous polypeptides
PH12012500982A1 (en)	2009-11-30	2019-07-10	Genentech Inc	Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
WO2011071577A1 (en)	2009-12-11	2011-06-16	Genentech, Inc.	Anti-vegf-c antibodies and methods using same
EP2516465B1 (en)	2009-12-23	2016-05-18	F.Hoffmann-La Roche Ag	Anti-bv8 antibodies and uses thereof
US20110159588A1 (en)	2009-12-30	2011-06-30	Kui Lin	Methods for Modulating a PDGF-AA Mediated Biological Response
MA34057B1 (fr)	2010-02-23	2013-03-05	Genentech Inc	Compositions et methodes pour le diagnostic et le traitement d'une tumeur
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
US10338069B2 (en)	2010-04-12	2019-07-02	Academia Sinica	Glycan arrays for high throughput screening of viruses
KR101860963B1 (ko)	2010-04-23	2018-05-24	제넨테크, 인크.	이종다량체 단백질의 생산
SG185027A1 (en)	2010-05-03	2012-11-29	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
NZ701208A (en)	2010-06-03	2016-05-27	Genentech Inc	Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
CA2807664A1 (en)	2010-08-12	2012-02-16	Theraclone Sciences, Inc.	Anti-hemagglutinin antibody compositions and methods of use thereof
CN103068846B9 (zh)	2010-08-24	2016-09-28	弗·哈夫曼-拉罗切有限公司	包含二硫键稳定性Fv片段的双特异性抗体
PT3556396T (pt)	2010-08-31	2022-07-04	Scripps Research Inst	Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
CN103328511B (zh)	2010-09-10	2016-01-20	埃派斯进有限公司	抗-IL-1β抗体及其使用方法
DK2625197T3 (en)	2010-10-05	2016-10-03	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
US9149959B2 (en)	2010-10-22	2015-10-06	Monosol Rx, Llc	Manufacturing of small film strips
SG191153A1 (en)	2010-12-23	2013-07-31	Hoffmann La Roche	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
RU2018108836A (ru)	2011-02-04	2019-03-14	Дженентек, Инк.	ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
WO2012112489A2 (en)	2011-02-14	2012-08-23	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
MX342810B (es)	2011-03-03	2016-10-13	Apexigen Inc	Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
BR112013023576A2 (pt)	2011-03-15	2016-12-06	Theraclone Sciences Inc	composições e métodos para a terapia e diagnóstico de influenza
ES2709654T3 (es)	2011-04-29	2019-04-17	Apexigen Inc	Anticuerpos anti-CD40 y métodos de uso
SG194735A1 (en)	2011-05-09	2013-12-30	Univ Virginia Patent Found	Compositions and methods for treating cancer
KR101972446B1 (ko)	2011-05-27	2019-04-25	글락소 그룹 리미티드	Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
KR20140068877A (ko)	2011-08-17	2014-06-09	제넨테크, 인크.	불응성 종양에서의 혈관신생의 억제
US8822651B2 (en)	2011-08-30	2014-09-02	Theraclone Sciences, Inc.	Human rhinovirus (HRV) antibodies
MX353958B (es)	2011-09-22	2018-02-07	Amgen Inc	Proteinas de union al antigeno cd27l.
MX2014004991A (es)	2011-10-28	2014-05-22	Genentech Inc	Combinaciones terapeuticas y metodos para tratar el melanoma.
EP2785742B1 (en)	2011-11-02	2020-01-08	Apexigen, Inc.	Anti-kdr antibodies and methods of use
PE20141937A1 (es)	2011-11-16	2014-12-18	Amgen Inc	Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
KR20140100571A (ko)	2011-12-08	2014-08-14	바이오테스트 아게	Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
JP2015502397A (ja)	2011-12-23	2015-01-22	ファイザー・インク	部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
CA2863224A1 (en)	2012-01-09	2013-07-18	The Scripps Research Institute	Ultralong complementarity determining regions and uses thereof
JP2015509091A (ja)	2012-01-09	2015-03-26	ザスクリプスリサーチインスティテュート	ヒト化抗体
CA2861124A1 (en)	2012-02-10	2013-08-15	Genentech, Inc.	Single-chain antibodies and other heteromultimers
AU2013229786B2 (en)	2012-03-08	2017-06-22	Halozyme, Inc.	Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9056910B2 (en)	2012-05-01	2015-06-16	Genentech, Inc.	Anti-PMEL17 antibodies and immunoconjugates
AR091069A1 (es)	2012-05-18	2014-12-30	Amgen Inc	Proteinas de union a antigeno dirigidas contra el receptor st2
RU2639287C2 (ru)	2012-06-27	2017-12-20	Ф. Хоффманн-Ля Рош Аг	Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
KR20150030744A (ko)	2012-06-27	2015-03-20	에프. 호프만-라 로슈 아게	표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
WO2014031498A1 (en)	2012-08-18	2014-02-27	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
LT3486248T (lt)	2012-09-26	2021-08-25	Immunogen, Inc.	Patobulinti maitansinolio acilinimo būdai
KR102270618B1 (ko)	2012-10-30	2021-06-30	아펙시젠, 인코포레이티드	항-cd40 항체 및 사용 방법
TW201425336A (zh)	2012-12-07	2014-07-01	Amgen Inc	Ｂｃｍａ抗原結合蛋白質
EP2948478B1 (en)	2013-01-25	2019-04-03	Amgen Inc.	Antibodies targeting cdh19 for melanoma
US9498532B2 (en)	2013-03-13	2016-11-22	Novartis Ag	Antibody drug conjugates
JP6436965B2 (ja)	2013-03-14	2018-12-12	ジェネンテック，インコーポレイテッド	抗ｂ７−ｈ４抗体及びイムノコンジュゲート
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
ES2701051T3 (es)	2013-03-15	2019-02-20	Novartis Ag	Conjugados de anticuerpo-fármaco
HUE056580T2 (hu)	2013-05-30	2022-02-28	Kiniksa Pharmaceuticals Ltd	Onkosztatin-M-receptor antigénjét kötõ fehérjék
EP3013365B1 (en)	2013-06-26	2019-06-05	Academia Sinica	Rm2 antigens and use thereof
EP3013347B1 (en)	2013-06-27	2019-12-11	Academia Sinica	Glycan conjugates and use thereof
WO2015017146A2 (en)	2013-07-18	2015-02-05	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
CA2918370A1 (en)	2013-07-18	2015-01-22	Fabrus, Inc.	Humanized antibodies with ultralong complementarity determining regions
EP3738611B1 (en)	2013-07-31	2025-09-03	BioNTech SE	Diagnosis and therapy of cancer involving cancer stem cells
JP6486368B2 (ja)	2013-09-06	2019-03-20	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
JP6282745B2 (ja)	2013-09-12	2018-02-21	ハロザイムインコーポレイテッド	修飾抗上皮成長因子受容体抗体およびその使用法
JP2016537399A (ja)	2013-09-17	2016-12-01	ジェネンテック，インコーポレイテッド	抗ｌｇｒ５抗体を使用する方法
CN105813654B (zh)	2013-10-11	2019-05-31	美国政府(由卫生和人类服务部的部长所代表)	Tem8抗体及其用途
WO2015069922A2 (en)	2013-11-06	2015-05-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Alk antibodies, conjugates, and chimeric antigen receptors, and their use
SG11201604784XA (en)	2013-12-13	2016-07-28	Genentech Inc	Anti-cd33 antibodies and immunoconjugates
WO2015095227A2 (en)	2013-12-16	2015-06-25	Genentech, Inc.	Peptidomimetic compounds and antibody-drug conjugates thereof
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en)	2014-01-16	2016-07-07	Academia Sinica	Compositions and methods for treatment and detection of cancers
EP3096797A1 (en)	2014-01-24	2016-11-30	F. Hoffmann-La Roche AG	Methods of using anti-steap1 antibodies and immunoconjugates
ES2694857T3 (es)	2014-02-04	2018-12-27	Genentech, Inc.	Smoothened mutante y métodos de uso de la misma
CN106415244B (zh)	2014-03-27	2020-04-24	中央研究院	反应性标记化合物及其用途
SG11201608192SA (en)	2014-04-11	2016-10-28	Medimmune Llc	Bispecific her2 antibodies
BR122021009041B1 (pt)	2014-05-06	2022-11-29	Genentech, Inc	Métodos para a preparação de uma proteína heteromultimérica
WO2015179658A2 (en)	2014-05-22	2015-11-26	Genentech, Inc.	Anti-gpc3 antibodies and immunoconjugates
CN106661099A (zh)	2014-05-27	2017-05-10	中央研究院	抗her2醣抗体及其用途
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2950415A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-cd20 glycoantibodies and uses thereof
JP7093612B2 (ja)	2014-05-27	2022-06-30	アカデミアシニカ	Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
WO2015184001A1 (en)	2014-05-28	2015-12-03	Academia Sinica	Anti-tnf-alpha glycoantibodies and uses thereof
MA40513A (fr)	2014-08-12	2017-06-21	Novartis Ag	Conjugués médicament-anticorps anti-cdh6
DK4074735T3 (da)	2014-08-28	2025-07-14	Bioatla Inc	Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
TWI745275B (zh)	2014-09-08	2021-11-11	中央研究院	使用醣脂激活人類ｉＮＫＴ細胞
MA40579A (fr)	2014-09-12	2016-03-17	Genentech Inc	Anticorps anti-cll-1 et immunoconjugués
WO2016040724A1 (en)	2014-09-12	2016-03-17	Genentech, Inc.	Anti-b7-h4 antibodies and immunoconjugates
LT3191135T (lt)	2014-09-12	2020-11-25	Genentech, Inc.	Anti-her2 antikūnai ir imunokonjugatai
HUE049175T2 (hu)	2014-09-23	2020-09-28	Hoffmann La Roche	Eljárás anti-CD79b immunkonjugátumok alkalmazására
RU2715905C2 (ru)	2014-10-01	2020-03-04	МЕДИММЬЮН, ЭлЭлСи	Способ конъюгации полипептида
CA2961439A1 (en)	2014-11-05	2016-05-12	Genentech, Inc.	Anti-fgfr2/3 antibodies and methods using same
EP3227332B1 (en)	2014-12-03	2019-11-06	F.Hoffmann-La Roche Ag	Multispecific antibodies
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
AU2016209056B2 (en)	2015-01-24	2021-01-28	Academia Sinica	Cancer markers and methods of use thereof
JP6779887B2 (ja)	2015-01-24	2020-11-04	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	新規なグリカンコンジュゲートおよびその使用方法
EP3253784B1 (en)	2015-02-04	2020-05-06	Genentech, Inc.	Mutant smoothened and methods of using the same
CA2979895A1 (en)	2015-03-18	2016-09-22	Immunobiochem Corporation	Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
WO2016165762A1 (en)	2015-04-15	2016-10-20	Ganymed Pharmaceuticals Ag	Drug conjugates comprising antibodies against claudin 18.2
WO2016172485A2 (en)	2015-04-24	2016-10-27	Genentech, Inc.	Multispecific antigen-binding proteins
EP4286511A3 (en)	2015-06-12	2024-03-06	Lentigen Technology, Inc.	Method to treat cancer with engineered t-cells
US20190194315A1 (en)	2015-06-17	2019-06-27	Novartis Ag	Antibody drug conjugates
CA3289997A1 (en)	2015-09-20	2026-03-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use
JP6821688B2 (ja)	2015-10-09	2021-01-27	ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉＢｉｏｔｅｃＴｅｃｈｎｏｌｏｇｙ，Ｉｎｃ．	キメラ抗原受容体および使用方法
MA43354A (fr)	2015-10-16	2018-08-22	Genentech Inc	Conjugués médicamenteux à pont disulfure encombré
CN108495653A (zh)	2016-01-27	2018-09-04	免疫医疗有限责任公司	用于制备具有定义的糖基化模式抗体的方法
EP3426693A4 (en)	2016-03-08	2019-11-13	Academia Sinica	PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
WO2017161206A1 (en)	2016-03-16	2017-09-21	Halozyme, Inc.	Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
SMT202600033T1 (it)	2016-04-15	2026-03-09	Bioatla Inc	Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi
US12433850B2 (en)	2016-05-05	2025-10-07	Aquestive Therapeutics, Inc.	Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en)	2016-05-05	2022-03-15	Aquestive Therapeutics, Inc.	Pharmaceutical compositions with enhanced permeation
WO2017192921A1 (en)	2016-05-05	2017-11-09	Monosol Rx, Llc	Enhanced delivery epinephrine compositions
US12427121B2 (en)	2016-05-05	2025-09-30	Aquestive Therapeutics, Inc.	Enhanced delivery epinephrine compositions
WO2017196847A1 (en)	2016-05-10	2017-11-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
PL3455261T3 (pl)	2016-05-13	2022-12-12	Bioatla, Inc.	Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
EP3465221B1 (en)	2016-05-27	2020-07-22	H. Hoffnabb-La Roche Ag	Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214182A1 (en)	2016-06-07	2017-12-14	The United States Of America. As Represented By The Secretary, Department Of Health & Human Services	Fully human antibody targeting pdi for cancer immunotherapy
EP3494135A1 (en)	2016-08-02	2019-06-12	The United States of America, as represented by The Secretary, Department of Health and Human Services	Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
CA3034057A1 (en)	2016-08-22	2018-03-01	CHO Pharma Inc.	Antibodies, binding fragments, and methods of use
ES2981703T3 (es)	2016-09-02	2024-10-10	Lentigen Tech Inc	Composiciones y métodos para tratar cáncer con DuoCars
EP4015532A1 (en)	2016-11-21	2022-06-22	cureab GmbH	Anti-gp73 antibodies and immunoconjugates
AU2017382883B2 (en)	2016-12-21	2024-07-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies specific for FLT3 and uses thereof
EP3565830B1 (en)	2017-01-09	2021-03-10	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-mesothelin immunotherapy
JOP20190187A1 (ar)	2017-02-03	2019-08-01	Novartis Ag	مترافقات عقار جسم مضاد لـ ccr7
CA3057838A1 (en)	2017-03-24	2018-09-27	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-cd33 immunotherapy
WO2018185618A1 (en)	2017-04-03	2018-10-11	Novartis Ag	Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018213064A1 (en)	2017-05-19	2018-11-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
AR111963A1 (es)	2017-05-26	2019-09-04	Univ California	Método y moléculas
WO2019006280A1 (en)	2017-06-30	2019-01-03	Lentigen Technology, Inc.	HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
WO2019005208A1 (en)	2017-06-30	2019-01-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019028051A1 (en)	2017-07-31	2019-02-07	Lentigen Technology, Inc.	COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
ES2960419T3 (es)	2017-09-15	2024-03-04	Lentigen Tech Inc	Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19
NZ762376A (en)	2017-09-19	2022-08-26	Scherrer Inst Paul	Transglutaminase conjugation method and linker
US10543263B2 (en)	2017-10-16	2020-01-28	Lentigen Technology Inc.	Compositions and methods for treating cancer with anti-CD22 immunotherapy
WO2019084057A2 (en)	2017-10-24	2019-05-02	Magenta Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
EP3703711A4 (en)	2017-11-03	2021-01-13	Lentigen Technology, Inc.	COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-MMR1 IMMUNOTHERAPY
CN119857155A (zh)	2017-11-29	2025-04-22	海德堡医药研究有限责任公司	用于耗尽cd5+细胞的组合物和方法
AU2018388997B2 (en)	2017-12-20	2025-04-03	Lentigen Technology, Inc.	Compositions and methods for treating HIV/AIDS with immunotherapy
US11939377B2 (en)	2018-07-12	2024-03-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Affinity matured CD22-specific monoclonal antibody and uses thereof
CA3107383A1 (en)	2018-07-23	2020-01-30	Magenta Therapeutics, Inc.	Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
EP3833684A1 (en)	2018-08-08	2021-06-16	The United States of America, as represented by the Secretary, Department of Health and Human Services	High affinity monoclonal antibodies targeting glypican-2 and uses thereof
EP3853254A1 (en)	2018-09-20	2021-07-28	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-cd123 immunotherapy
JP7546554B2 (ja)	2018-09-26	2024-09-06	レンティジェン・テクノロジー・インコーポレイテッド	抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
CN119592592A (zh)	2018-11-30	2025-03-11	莱蒂恩技术公司	用于用抗cd38免疫治疗来治疗癌症的组合物和方法
BR112021010908A2 (pt)	2018-12-06	2021-08-31	Genentech, Inc.	Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
CA3125484A1 (en)	2019-01-08	2020-07-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cross-species single domain antibodies targeting mesothelin for treating solid tumors
US12122843B2 (en)	2019-01-22	2024-10-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN113924103B (zh)	2019-03-06	2025-02-14	莱蒂恩技术公司	用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
CA3128571A1 (en)	2019-03-19	2020-09-24	Paul Scherrer Institut	Transglutaminase conjugation method with a glycine based linker
AU2020275415B2 (en)	2019-05-14	2026-01-15	Genentech, Inc.	Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
CA3140102A1 (en)	2019-05-30	2020-12-03	Dina SCHNEIDER	Compositions and methods for treating cancer with anti-bcma immunotherapy
WO2021003297A1 (en)	2019-07-02	2021-01-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind egfrviii and their use
WO2021010326A1 (ja)	2019-07-12	2021-01-21	中外製薬株式会社	抗変異型ｆｇｆｒ３抗体およびその使用
WO2021076196A1 (en)	2019-10-18	2021-04-22	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CA3156761A1 (en)	2019-10-22	2021-04-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
WO2021118968A1 (en)	2019-12-12	2021-06-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibody-drug conjugates specific for cd276 and uses thereof
CN115916822A (zh)	2020-04-24	2023-04-04	基因泰克公司	使用抗CD79b免疫缀合物的方法
US20230181756A1 (en)	2020-04-30	2023-06-15	Novartis Ag	Ccr7 antibody drug conjugates for treating cancer
US11497770B2 (en)	2020-06-22	2022-11-15	Lentigen Technology, Inc.	Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
KR20230069211A (ko)	2020-09-18	2023-05-18	아라리스 바이오테크 아게	아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법
KR20230096052A (ko)	2020-10-25	2023-06-29	아라리스 바이오테크 아게	항체-링커 접합체를 생성하기 위한 수단 및 방법
US20230391852A1 (en)	2020-10-26	2023-12-07	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies targeting sars coronavirus spike protein and uses thereof
AU2021372997A1 (en)	2020-11-05	2023-06-22	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
WO2022232612A1 (en)	2021-04-29	2022-11-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Lassa virus-specific nanobodies and methods of their use
IL308351A (en)	2021-05-12	2024-01-01	Genentech Inc	Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
CN117396513A (zh)	2021-05-28	2024-01-12	葛兰素史密斯克莱知识产权发展有限公司	治疗癌症的联合疗法
US20240270851A1 (en)	2021-06-09	2024-08-15	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Cross species single domain antibodies targeting pd-l1 for treating solid tumors
US11807685B2 (en)	2021-08-05	2023-11-07	The Uab Research Foundation	Anti-CD47 antibody and uses thereof
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CA3233953A1 (en)	2021-10-05	2023-04-13	Matthew Bruce	Combination therapies for treating cancer
US12465564B2 (en)	2021-10-25	2025-11-11	Aquestive Therapeutics, Inc.	Oral and nasal compositions and methods of treatment
WO2023072934A1 (en)	2021-10-25	2023-05-04	Araris Biotech Ag	Methods for producing antibody-linker conjugates
KR20240150807A (ko)	2022-02-22	2024-10-16	아라리스 바이오테크 아게	2개 이상의 페이로드를 포함하는 펩티드 링커
US11590169B1 (en)	2022-03-02	2023-02-28	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20230338424A1 (en)	2022-03-02	2023-10-26	Lentigen Technology, Inc.	Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
CN119923410A (zh)	2022-07-28	2025-05-02	莱蒂恩技术公司	用于治疗实体瘤的嵌合抗原受体治疗
WO2024044743A1 (en)	2022-08-26	2024-02-29	Lentigen Technology, Inc.	Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
WO2024218345A1 (en)	2023-04-21	2024-10-24	Glaxosmithkline Intellectual Property Development Limited	Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
KR20260021689A (ko)	2023-06-08	2026-02-13	제넨테크, 인크.	림프종 진단 및 치료 방법을 위한 대식세포 시그니처
WO2025014896A1 (en)	2023-07-07	2025-01-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Humanized 40h3 antibody
AU2024295016A1 (en)	2023-07-20	2026-02-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025078841A2 (en)	2023-10-11	2025-04-17	Antikor Biopharma Limited	Antibodies, conjugates, and uses thereof
WO2025082990A1 (en)	2023-10-15	2025-04-24	Araris Biotech Ag	Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2025171238A1 (en)	2024-02-07	2025-08-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
US20260000765A1 (en)	2024-06-27	2026-01-01	Lentigen Technology, Inc.	CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS
WO2026013234A1 (en)	2024-07-10	2026-01-15	Araris Biotech Ag	Triple-payload antibody-drug conjugates (adcs)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3896111A (en) *	1973-02-20	1975-07-22	Research Corp	Ansa macrolides
US4137230A (en) *	1977-11-14	1979-01-30	Takeda Chemical Industries, Ltd.	Method for the production of maytansinoids
US4265814A (en) *	1978-03-24	1981-05-05	Takeda Chemical Industries	Matansinol 3-n-hexadecanoate
JPS5562090A (en) *	1978-10-27	1980-05-10	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS5566586A (en) *	1978-11-14	1980-05-20	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS5566585A (en) *	1978-11-14	1980-05-20	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation

1979
- 1979-06-08 JP JP7281179A patent/JPS55164685A/ja active Pending
1980
- 1980-05-22 US US06/152,392 patent/US4317821A/en not_active Expired - Lifetime
- 1980-06-06 CA CA000353518A patent/CA1135260A/en not_active Expired
- 1980-06-06 EP EP80103138A patent/EP0021178B1/en not_active Expired
- 1980-06-06 AT AT80103138T patent/ATE5885T1/de active
- 1980-06-06 DE DE8080103138T patent/DE3066149D1/de not_active Expired

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008528493A (ja) *	2005-01-21	2008-07-31	イミュノジェン・インコーポレーテッド	メイタンシノイドエステル類を調製するための方法
JP2014012693A (ja) *	2005-01-21	2014-01-23	Immunogen Inc	メイタンシノイドエステル類を調製するための方法

Also Published As

Publication number	Publication date
EP0021178B1 (en)	1984-01-18
US4317821A (en)	1982-03-02
CA1135260A (en)	1982-11-09
DE3066149D1 (en)	1984-02-23
EP0021178A1 (en)	1981-01-07
ATE5885T1 (de)	1984-02-15

Publication	Publication Date	Title
JPS55164685A (en)	1980-12-22	Novel maytansinoid compound and its preparation
JPS5615299A (en)	1981-02-14	Rhodomycin group antibiotic and its preparation
JPS5432460A (en)	1979-03-09	Cycloalkylidenemethylphenylacetic acid derivative and their preparation
JPS5663966A (en)	1981-05-30	Pyrimidine derivative and its preparation
JPS5791997A (en)	1982-06-08	5'-o-acylnucleoside and its preparation
JPS5655389A (en)	1981-05-15	Benzo ij quinolidine-2-carboxylic acid derivative, and its preparation
JPS56131586A (en)	1981-10-15	Triazolopyrimidine derivative and its preparation
JPS57118555A (en)	1982-07-23	Leucotriene-analog compound, its preparation, and leucotriene-biosynthesis inhibiting agent containing said compound as active component
JPS5716852A (en)	1982-01-28	Nitrile derivative, its preparation, and fibrosis suppressing agent containing the same
JPS5772981A (en)	1982-05-07	1,8-naphthyridine derivative and its salt
JPS5651460A (en)	1981-05-09	Pyrimidine derivative, its preparation, and antitumor agent comprising its derivative
JPS527994A (en)	1977-01-21	Process for preparing novel pyrimido (4,5-d) pyrimidine derivatives
JPS5687595A (en)	1981-07-16	Novel bioactive substance herbimycin b, its preparation, and agricultural and horticultural agent containing said substance as effective component
JPS55145700A (en)	1980-11-13	25-hydroxy-24-oxo-5beta-cholestane derivative and its preparation
JPS5612393A (en)	1981-02-06	Novel camptothecin derivative
JPS5663991A (en)	1981-05-30	Glucosamine derivative and its preparation
JPS5553294A (en)	1980-04-18	Novel ansamitocin derivative and its preparation
JPS57140785A (en)	1982-08-31	Benzothiazine derivative, its preparation, and pharmaceutical composition containing the same
JPS5430172A (en)	1979-03-06	Pyrazolidine derivative
JPS5728066A (en)	1982-02-15	Glycerol derivative of 5-fluorouracil
JPS56128787A (en)	1981-10-08	Cephalosporin derivative and its preparation
JPS57163383A (en)	1982-10-07	Neplanocin a derivative
JPS5227796A (en)	1977-03-02	Process for preparing novel pyrimido (4,5-d) pyrimidinedione derivativ es
JPS5543059A (en)	1980-03-26	2-amino-dipyrido (1,2-a; 3',2'-d) imidazole derivative, its preparation and mutagenic agent therefrom
JPS55102548A (en)	1980-08-05	Nitrosamine derivative